Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(1.20)
# 3,508
Out of 4,761 analysts
8
Total ratings
37.5%
Success rate
-1.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Initiates: Buy | $68 | $67.96 | +0.06% | 1 | Jan 10, 2025 | |
| CING Cingulate | Initiates: Buy | $12 | $4.27 | +181.03% | 1 | Jan 10, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Initiates: Buy | $7 | $1.57 | +345.86% | 1 | Jan 10, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 | $2.27 | +208.37% | 2 | Dec 24, 2024 | |
| CRVO CervoMed | Initiates: Buy | $45 | $2.28 | +1,873.68% | 1 | Dec 5, 2024 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $13.04 | +122.39% | 1 | Dec 5, 2024 | |
| LGVN Longeveron | Initiates: Buy | $10 | $1.56 | +541.03% | 1 | Dec 5, 2024 |
Verona Pharma
Jan 10, 2025
Initiates: Buy
Price Target: $68
Current: $67.96
Upside: +0.06%
Cingulate
Jan 10, 2025
Initiates: Buy
Price Target: $12
Current: $4.27
Upside: +181.03%
Reviva Pharmaceuticals Holdings
Jan 10, 2025
Initiates: Buy
Price Target: $7
Current: $1.57
Upside: +345.86%
Gain Therapeutics
Dec 24, 2024
Maintains: Buy
Price Target: $7
Current: $2.27
Upside: +208.37%
CervoMed
Dec 5, 2024
Initiates: Buy
Price Target: $45
Current: $2.28
Upside: +1,873.68%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $13.04
Upside: +122.39%
Longeveron
Dec 5, 2024
Initiates: Buy
Price Target: $10
Current: $1.56
Upside: +541.03%